Table 2.
Examples of biofilm studies in clinical human DFU.
Model | N° of Patients | Biofilm Visualization | Findings | Reference |
---|---|---|---|---|
DFU | 2 | CLSM | Evidence of biofilms | [44] |
DFU | 162 | Microtiter plate assay | Biofilms in 67.9% of infected DFUs | [45] |
DFU | 26 | FISH and ESEM | Observation of the formed biofilms and their bacterial constitution | [48] |
DFU | 357 | Crystal violet | Observation of the formed biofilms | [46] |
DFU | 100 | Congo Red dye, tissue culture plates, and crystal violet staining | Biofilm formation in 46.3% of isolates, predominantly by S. aureus (38.8% of isolates) and MDR bacteria (46.3%) | [47] |
DFU | 49 | Calgary biofilm pin lid device with resazurin and PCR of genes associated with biofilm formation | Biofilms are resistant to antibiotics at concentrations 10–1000 times higher than those required to kill planktonic cells | [53] |
DFU | 155 | Microtiter plate assay and ELISA, XTT formazan, and SEM | Presence and importance of non-Candida albicans species in biofilms | [55] |
DFU | 95 | Microtiter plate assay and FISH | Polymicrobial biofilms are thicker | [56] |
DFU—diabetic foot ulcer; CLSM—confocal laser scanning microscopy; ELISA—enzyme-linked immunosorbent assay; ESEM—environmental scanning electron microscopy; FISH—fluorescent in situ hybridization; MDR—multidrug resistant; PIA—polysaccharide intercellular adhesin; SEM—scanning electron microscopy; XTT—2H-tetrazolium-5-carboxanilide.